NCT02752191View on ClinicalTrials.gov

Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 19, 2018

Study Completion Date

December 19, 2018

Conditions
Pediatric Congenital Heart Disease
Interventions
DRUG

ferumoxytol

ferumoxytol as an MRI contrast agent infused over several minutes

DRUG

gadofosveset

gadofosveset as an MRI contrast agent injected over several seconds

Trial Locations (1)

90095

UCLA Medical Center, Los Angeles

All Listed Sponsors
lead

Paul Finn

OTHER

NCT02752191 - Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease | Biotech Hunter | Biotech Hunter